big board momo plays. long and short.
Followers | 281 |
Posts | 15,374 |
Boards Moderated | 1 |
Alias Born | 03/07/2012 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Godzilla . It was AWESOME!.
Damn that looks good.
Good morning AT.
Good morning SMART MONEY board.
Provectus Biopharmaceuticals, Inc.'s Common Shares to Begin Trading on NYSE MKT
Symbol Remains “PVCT”
Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced that its shares will begin trading on the NYSE MKT today, Friday, May 16, 2014. The company’s ticker symbol will remain “PVCT” but it will withdraw its shares from quotation on the OTCQB concurrent with listing its shares on the NYSE MKT.
Dr. Craig Dees, PhD, CEO of Provectus said, "Listing on the NYSE MKT is a huge milestone for Provectus Biopharmaceuticals, and I take a great deal of personal satisfaction from this news. I believe that this will enhance our shareholder value as well as broaden our shareholder base and heighten our corporate profile in the capital markets.”
NYSE MKT is a fully integrated trading venue within the NYSE Euronext community and leverages the NYSE’s advanced and innovative market model to offer a premier venue for listing and trading the stocks of small companies. The venue utilizes the trading, connectivity and routing technologies of the NYSE platform and offers superior price discovery, superior liquidity and reduced trading volatility. Listed companies benefit from issuer-selected Designated Market Makers (DMM) that utilize world-class NYSE trading systems to discover and improve prices, dampen volatility, add liquidity and enhance value. In addition, NYSE MKT-listed companies gain access to the brand visibility and are eligible for the issuer services enjoyed by the NYSE Euronext community.
“We welcome Provectus to the NYSE community and look forward to a strong partnership with the Company and its shareholders,” said Scott Cutler, Executive Vice President and Head of Global Listings at NYSE Euronext. “Provectus will join other pharmaceutical companies that benefit from NYSE’s trusted and reliable platform to raise capital.”
All eyes on PVCT this morning. Closed at 3.40.
Good morning guys. TGIF to everyone here.
MyECheck Reports $1.3 Million Net Earnings in the First Quarter 2014
MyECheck Reports $1.3 Million Net Earnings in the First Quarter 2014
EL DORADO HILLS, CA--(Marketwired - May 15, 2014) - MyECheck, Inc. (OTC Pink: MYEC) (PINKSHEETS: MYEC), the leading developer and licensor of electronic check services, today reported Q1 2014 results. For the three months ended March 31, 2013, revenue from operations was $1,361,783, total expenses were $37,737, and net income was $1,323,656.
Cash and cash receivables were increased to $1,687,068, and as of May 15, the Company has $1,078,964 in cash. Stockholders equity was increased from a $1.2 million shareholder deficit in the same period previous year, to almost $1.2 million in shareholder equity.
During the quarter, the company sold a number of licenses for it's new mobile payment app system, including custom developed apps with unique security features for specific targeted industries.
The company re-purchased at par value and cancelled 1 billion shares of its common stock in the first quarter.
The company hired a new CFO, a new COO and a seated a new Board Director also during the quarter.
MyECheck engaged auditors to audit its financial records dating back from 2009 to current. The company expects that the audit will be complete before the next reporting deadline, August 15 2014, and that complete audited financial statements from 2009 to current will be available at that time for filing with the appropriate reporting agency.
The Company also has been sponsored by Glendale Securities for its application for electronic clearing of its shares through the Depository Trust Company "DTC", and is awaiting final approval for DTC eligibility, currently pending.
GrowLife Releases Initial 2014 Results, Posts $2.38 Million in Q1 Revenue, a 213% Year Over Year Increase
WOODLAND HILLS, Calif., May 15, 2014 /PRNewswire/ -- GrowLife, Inc., (OTC: PHOT), the recognized leader in specialty hydroponics and an essential facilitator of the grower marketplace, announced the timely filing of its 10Q report and financial results for the quarter ending March 31, 2014. The full 10Q filing is available in its entirety at www.GrowLifeInc.com or on the SEC's website http://edgar.sec.gov/.
GrowLife revenues for its first financial quarter of 2014 increased to $2,382,836, from $760,709 in the same period last year, an increase of $1,622,127 or 213% compared against revenues in Q1 2013. By the same measures, gross profit increased $270,752 comparing the respective quarters, or 108%.
"We are very pleased with the Q1 2014 financial results, as the revenue growth exceeded our internal goals for Q1," stated GrowLife CEO and Chairman Sterling Scott. "We continue to witness a strong revenue growth trajectory moving in the right direction, and GrowLife management will increase efforts on our gross and net margins company-wide, while maintaining relatively high growth rates. GrowLife remains dedicated to growth, increasing scale and continued expansion of company operations across all of our market sectors."
Notwithstanding our growth and improving record of quarter over quarter revenue expansion, the industry and GrowLife as an essential B2B (business to business) and B2C (business to end customer) facilitator have significant challenges. Importantly, our industry overall continues to struggles with credit availability and normalized banking. Over time, we expect that for the industry overall and for GrowLife, these matters will stabilize in an acceptable manner to support expansion. In the interim, we regard the credit and normalized banking issues as very substantial competitive business opportunities for GrowLife.
As our Q1 2014 10Q results indicate, GrowLife has continued to incur substantial non-cash charges in Q1 2014; management is dedicated to actively reducing non-cash charges going forward and, as part of our continuing commitment to transparency, management will at the earliest possible time provide details of our strategy to reduce non-cash charge issues in the future. The legislative environment continues to shift favorably for legal cannabis, albeit with some fits and starts affecting banking and credit for the industry and the Company. GrowLife remains well positioned to further increase our market leading presence in a revenue diversified manner that is profitable to the Company and its shareholders.
From time to time, GrowLife will provide market updates and news via its websites GrowLifeInc.com, Cannabis.org or the Company's Facebook page at https://www.facebook.com/tellthetruthfederalgovernment
What's up old friend. It's so funny I just watched a trailer of GOTHAM and you message me. Who are you driving nuts now?
It's rocking
20 mill on the bid now
Lol. You still at it. Let me guess you bought .0003s without doing your homework.
Lol. You guys are like the blind leading the blind. Too easy.
Nice job ANG. At .0078 now.
Getting perky
On watch for me also. NEWL.
Dude it's triple 0 .
In NYXO. Nice job guys.
Sold MFTH. In NYXO.
Nice job calling MFTH. Nice catch.
PMCM with news out this morning.
Good morning ANG. Caught MFTH on my scanner before close. Got some 5s for a lotto. Just had to do it. Lol.
Right behind you. Got some 5s. Good luck MFTH.
That would have been good.
It's been rumored all over twitter for days now of impending halt. Hope no one here got in.
Gotcha . Was only posting the news. I think I remember that garbage too. I'll be more careful what tickers I post news on. Thanks BEACHLOVER.
Epazz Signs Purchase Agreement to Acquire Audit Compliance Software Company; Expects to Add $500,000 to Revenue Stream
Epazz Signs Purchase Agreement to Acquire Audit Compliance Software Company; Expects to Add $500,000 to Revenue Stream
CHICAGO, IL--(Marketwired - May 14, 2014) - Epazz, Inc. (OTC Pink: EPAZ) (PINKSHEETS: EPAZ), a leading provider of cloud based business software solutions announced that the Company has signed a purchase agreement to acquire an Audit Compliance Software Company in the Midwest U.S. This new acquisition is expected to provide substantial growth to Epazz's revenue stream by bringing in $500,000 in revenues in the first year. The unaudited revenues for 2013 were over $500,000.
The target company was founded in 2000s and has a long history of positive cash flow and profitability. The software product is considered to be truly unique and there are few competitors presently in the market offering such an all-encompassing suite of software within their target market thereby making this move quite strategic in Epazz, Inc.'s projected growth.
Epazz has been increasing its global distribution channels and continues to search for suitable acquisitions. Epazz, Inc.'s CEO, Shaun Passley, Ph.D., noted, "This acquisition will be immediately accretive to our revenue and profit stream. It will provide a solid customer base and it opens up many opportunities to cross sell customers on Epazz's BoxesOS portal software, DeskFlex room scheduling software, Agent Power workforce management software, Intellisys energy management software, AutoHire applicant tracking system, K9 Bytes kennel software and MS Health emr software. With the synergies of our companies the customers can continue to look forward to innovative, effective and efficient software tools geared to enhancing their business process."
Epazz, Inc. is in negotiations to acquire several other B2B software companies. Epazz, Inc.'s action is a clear reflection of its long term strategic growth plan to acquire profitable B2B software companies.
About Epazz Inc. (www.epazz.com)
BioElectronics' OTC ActiPatch® Musculoskeletal Pain Therapy Clinically Proven to Reduce Osteoarthritis Pain and Disability
FREDERICK, Md., May 14, 2014 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced drug-free consumer medical devices, today announced more detail on the interim results of a randomized, double blind, placebo controlled trial on osteoarthritis of the knee (knee pain) using ActiPatch® Therapy. The interim results are now published online at the EULAR (European League against Arthritis) conference website at https://b-com.mci-group.com/AbstractList/EULAR2014.aspx and search for abstract #: AB0777.
"Arthritis is the major cause of disability in the US affecting 52.5 million adults. Osteoarthritis of the knee is the most common musculoskeletal pain and disability condition. Therefore we are extremely pleased by the results of Dr. Gianluca Bagnato's clinical study," commented Ian Rawe, Ph.D. Director of Research, BioElectronics. Dr. Rawe noted that the study looked at three important measures associated with Osteoarthritis, these being pain, ease of movement and overall patient quality of life. "Importantly the study results show significant improvement in all three measures for the group wearing the active ActiPatch device relative to the group wearing the non-active device. We take these results as strong support for our contention that our affordable innovative drug-free technology can greatly reduce disabilities, physician office visits, and the reliance on drugs for chronic pain."
ActiPatch® Musculoskeletal Pain Therapy devices are readily available, over-the-counter outside of the US, for approximately $30.00, or $0.04 per hour of therapy.
The specific four weeks of ActiPatch® Therapy showed the following:
Patients treated with ActiPatch® Therapy showed a statistically significant improvement in visual analogue pain scores (VAS) (p<0.005) and WOMAC* pain scores (p<0.001) at 4 weeks compared to baseline.
Patients treated with ActiPatch® Therapy assessed for function and disability showed statistically significant improvement for WOMAC* function (p<0.002) and WOMAC* stiffness (p<0.02) at 4 weeks compared to baseline.
Patients treated with ActiPatch® Therapy also demonstrated statistically significant (p<0.04) improved physical and mental health as assessed by the SF-36 (36-item Medical Outcomes Study Short-Form 36 version 2) at 4 weeks compared to baseline.
No statistically significant results were recorded in the placebo group.
[*WOMAC - Western Ontario and McMaster Universities Osteoarthritis Index]
Other Clinical Research
BioElectronics is conducting a series of clinical research studies using its medical devices. Details can be found at http://www.bielcorp.com/clinical-evidence/ along with details of previously completed and published clinical trials.
GOOD MORNING guys. ICLD, PLUG, PGFY, NYBD, and BMSN all on watch for me this morning. Let's make money!
PGFY! Who's on that one?
Thanks brother. BMSN on fire again.
Visiting. Great job with the board. Looks like I have a lot of catching up to do. FNMA just amazing.
Good morning board
VNDM and VFIN diluting.
Somebody what's in bad. Bid support growing.
.0004s are about to go soon.
How you know? Don't be hating!
7 million hit at .0001. Looks like this play is over.